FDA Brief

Warning letters Drugs

FDA warning letter to

Spartan Chemical Company, Inc.

High riskIssued Dec 15, 2021Posted Dec 28, 2021Division of Pharmaceutical Quality Operations III

FDA found B. cepacia contamination and CGMP failures at Spartan Chemical’s hand sanitizer plant, plus unapproved COVID-19 claims.

What happened

FDA inspected Spartan Chemical’s Maumee, Ohio drug manufacturing facility from March 1 to 26, 2021. FDA laboratory testing of Lite’n Foamy Lemon Blossom Hand Sanitizer lot 538756 found Burkholderia cepacia complex and high total microbial and yeast/mold counts. FDA also reviewed the company’s website on October 8, 2021 and labeling, and found COVID-19 claims and statements that products were FDA registered and approved.

What FDA found

  1. Spartan used water from a system that lacked performance qualification and routine monitoring to make aqueous drug products.

    21 CFR 211.100(a)
  2. Spartan’s investigations of failing microbial results, including B. cepacia contamination, did not find root cause, assess distributed batches, or require effective corrective actions.

    21 CFR 211.192
  3. Spartan’s quality unit did not adequately oversee manufacturing, change control, product reviews, training, or microbial testing such as B. cepacia suitability and antimicrobial effectiveness testing.

    21 CFR 211.22
  4. FDA found B. cepacia complex and high total microbial and yeast/mold counts in Lite’n Foamy Lemon Blossom Hand Sanitizer lot 538756, showing insanitary manufacturing conditions.

    FD&C Act section 501(a)(2)(A), 21 U.S.C. 351(a)(2)(A)
  5. The foamyiQ and Lite’n Foamy antiseptic products were marketed with COVID-19 claims without an approved new drug application.

    FD&C Act section 505(a), 21 U.S.C. 355(a)
  6. The products’ labeling falsely stated they were FDA registered and approved.

    FD&C Act sections 502(a) and (ee), 21 U.S.C. 352(a) and (ee)

What FDA wants

FDA asks Spartan to provide comprehensive remediation plans and independent assessments for its water system, investigations and CAPA, quality unit, change control, cleaning validation, and antimicrobial effectiveness testing. The provided letter does not state a response deadline.

Who should pay attention

  • brands and distributors that sell Spartan hand sanitizers
  • contract manufacturers of water-based OTC antiseptics
  • quality units responsible for water systems and microbial investigations

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. CNC Noodle Corporation

    FDA warned CNC Noodle Corporation that its Hayward, California noodle plant had insanitary conditions, no pathogen or allergen controls, and mislabeled products.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Northland Nuclear Medicine, LLC

    FDA warned Northland Nuclear Medicine in Bismarck, ND, that its PET drugs are adulterated because it failed to investigate microbial contamination and low yields.

    High risk